This is the 142nd ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing.
Company is investing more than €100 million in the expansion of the Halle site
Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions
_256_384.jpg){kind=logo}
Meets the growing need for US-based API solubility and bioavailability enhancement services
Pfizer aims to achieve net-zero targets ten years earlier than the expectations of the Net-Zero Standard
Govt committed to supporting pharma companies with industry-friendly policies
Prior to this, Maria held multiple roles at Novartis including Head of Global Manufacturing Functions, and Global Head of Manufacturing, Science & Technology
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
Subscribe To Our Newsletter & Stay Updated
